Genetically increased risk of sleep disruption in Alzheimer's disease

Sleep

Volumn 29, Issue 8, 2006, Pages 1003-1007

  Craig, David ^a   Hart, Dominic J ^a   Passmore, A Peter ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Alzheimer's disease; Monoamine oxidase A; Polymorphism; Sleep

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A;

ADULT; ALLELE; ALZHEIMER DISEASE; ARTICLE; CAREGIVER; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROBIOLOGY; NEUROTRANSMITTER RELEASE; PRIORITY JOURNAL; PROMOTER REGION; RISK ASSESSMENT; SLEEP DISORDER; STRESS;

EID: 33747479175     PISSN: 01618105     EISSN: None     Source Type: Journal    
DOI: 10.1093/sleep/29.8.1003     Document Type: Article

References (43)

1. Moran M, Lynch CA, Walsh C, Coen R, Coakley D, Lawlor BA. Sleep disturbance in mild to moderate Alzheimer's disease. Sleep Med 2005;6:347-52.
2. Carpenter BD, Strauss ME, Patterson MB. Sleep disturbances in community dwelling patients with Alzheimer's disease. Clin Gerontol 1995;16:35-49.
3. McCurry SM, Logsdon RG, Vitiello MV, Teri L. Successful behavioral treatment for reported sleep problems in elderly caregivers of dementia patients: a controlled study. J Gerontol B Psychol Sci Soc Sci 1998;53:122-9.
4. Hope T, Keene J, Gedling K, Fairburn CG, Jacoby R. Predictors of institutionalization for people with dementia living at home with a carer. Int J Geriatr Psychiatry 1998;13:682-90.
5. Pollak CP, Perlick D. Sleep problems and institutionalization of the elderly. J Geriatr Psychiatry Neurol 1991;4:204-10.
6. Donaldson C, Tarrier N, Burns A. Determinants of carer stress in Alzheimer's disease. Int J Geriatr Psychiatry 1998;13:248-56.
7. McCurry SM, Logsdon RG, Teri L, et al. Characteristics of sleep disturbance in community-dwelling Alzheimer's disease patients. J Geriatr Psychiatry Neurol. 1999;12:53-9.
8. Tractenberg RE, Singer CM, Cummings JL, Thai LJ. The Sleep Disorders Inventory: an instrument for studies of sleep disturbance in persons with Alzheimer's disease. J Sleep Res 2003;12:331-7.
9. Singer C, Tractenberg RE, Kaye J, et al. Alzheimer's Disease Cooperative Study. A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease. Sleep 2003;26:893-901.
10. McCurry SM, Ancoli-Israel S. Sleep Dysfunction in Alzheimer's Disease and Other Dementias. Curr Treat Options Neurol 2003;5:261-72.
11. Mishima K, Tozawa T, Satoh K, Matsumoto Y, Hishikawa Y, Okawa, M. Melatonin secretion rhythm disorders in patients with senile dementia of Alzheimer's type with disturbed sleep-waking. Biol Psychiatry 1999;45:417-21.
12. Ohashi Y, Okamoto N, Uchida K, Iyo M, Mori N, Morita Y. Daily rhythm of serum melatonin levels and effect of light exposure in patients with dementia of the Alzheimer's type. Biol Psychiatry 1999;45:1646-52.
13. Ferrari E, Arcaini A, Gornati R, et al. Pineal and pituitary- adrenocortical function in physiological aging and in senile dementia. Exp Gerontol 2000;35:1239-50.
14. Palmer AM, Dekosky ST. Monoamine neurons in aging and Alzheimer's disease. J Neural Transm Gen Sect 1993;91:135-59.
15. Widner B, Ledochowski M, Fuchs D. Sleep disturbances and tryptophan in patients with Alzheimer's disease. Lancet 2000;355:755-6.
16. Wu YH, Swaab DF. The human pineal gland and melatonin in aging and Alzheimer's disease. J Pineal Res 2005;38:145-52.
17. Pardo CA, Martin LJ, Troncoso JC, Price DL. The human pineal gland in aging and Alzheimer's disease: patterns of cytoskeletal antigen immunoreactivity. Acta Neuropathol (Berl) 1990;80:535-40.
18. van de Nes JA, Kamphorst W, Ravid R, Swaab DF. Comparison of beta-protein/A4 deposits and Alz-50-stained cytoskeletal changes in the hypothalamus and adjoining areas of Alzheimer's disease patients: amorphic plaques and cytoskeletal changes occur independently. Acta Neuropathol (Berl) 1998;96:129-38.
19. Stopa EG, Volicer L, Kuo-Leblanc V, et al. Pathologic evaluation of the human suprachiasmatic nucleus in severe dementia. J Neuropathol Exp Neurol 1999;58:29-39.
20. Liu RY, Zhou JN, van Heerikhuize J, Hofman MA, Swaab DF. Decreased melatonin levels in postmortem cerebrospinal fluid in relation to aging, Alzheimer's disease, and apolipoprotein E-epsilon4/4 genotype. J Clin Endocrinol Metab 1999;84:323-7.
21. Cacabelos R, Rodriguez B, Carrera C, et al. APOE-related frequency of cognitive and noncognitive symptoms in dementia. Meth Find Exp Clin Pharmacol 1996;18:693-706.
22. Robertson J, Curley J, Kaye J, Quinn J, Pfankuch T, Raber J. apoE isoforms and measures of anxiety in probable AD patients and Apoe-/- mice. Neurobiol Aging 2005;26:637-43.
23. Yesavage JA, Friedman L, Kraemer H, et al. Sleep/wake disruption in Alzheimer's disease: APOE status and longitudinal course. Geriatr Psychiatry Neurol 2004;17:20-4
24. Koch H, Craig I, Dahlitz M, Denney R, Parkes D. Analysis of the monoamine oxidase genes and the Norrie disease gene locus in narcolepsy. Lancet 1999;353:645-6.
25. Dauvilliers Y, Neidhart E, Lecendreux M, Billiard M, Tafti M. MAO-A and COMT polymorphisms and gene effects in narcolepsy. Mol Psychiatry 2001;6:367-72.
26. Frauscher B, Hogl B, Maret S, et al. Association of daytime sleepiness with COMT polymorphism in patients with parkinson disease: a pilot study. Sleep 2004;27:733-6.
27. Desautels A, Turecki G, Montplaisir J, et al. Evidence for a genetic association between monoamine oxidase A and restless legs syndrome. Neurology 2002;59:215-9.
28. Du L, Bakish D, Ravindran A, Hrdina PD. MAO-A gene polymorphisms are associated with major depression and sleep disturbance in males. Neuroreport 2004;15:2097-101.
29. Tollefson GD. Monoamine oxidase inhibitors: a review. J Clin Psychiatry. 1983;44:280-8.
30. Wu YH, Feenstra MG, Zhou JN, et al. Molecular changes underlying reduced pineal melatonin levels in Alzheimer disease: alterations in preclinical and clinical stages. J Clin Endocrinol Metab 2003;88:5898-906.
31. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44.
32. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
33. Resiberg B. Functional assessment staging (FAST). Psychopharmacol Bull 1988;24:653-9.
34. Kaufer DI, Cummings JL, Christine D, et al. Assessing the impact of neuropsychiatric symptoms in Alzheimer's disease: the Neuropsychiatric Inventory Caregiver Distress Scale. J Am Geriatr Soc 1998;46:210-5.
35. McIlroy SP, Vahidassr MD, Savage DA, Patterson CC, Lawson JT, Passmore AP. Risk of Alzheimer's disease is associated with a very low-density lipoprotein receptor genotype in Northern Ireland. Am J Med Genet 1999;88:140-4.
36. Matsumoto C, Shinkai T, Hori H, Ohmori O, Nakamura J. Polymorphisms of dopamine degradation enzyme (COMT and MAO) genes and tardive dyskinesia in patients with schizophrenia. Psychiatry Res 2004;127:1-7.
37. Cacabelos R, Rodriguez B, Carrera C, Beyer K, Lao JI, Sellers MA. Behavioral changes associated with different apolipoprotein E genotypes in dementia. Alzheimer Dis Assoc Disord 1997;11:S27-34.
38. McCurry SM, Reynolds CF, Ancoli-Israel S, Teri L, Vitiello MV. Treatment of sleep disturbance in Alzheimer's disease. Sleep Med Rev 2000;4:603-28.
39. Takehashi M, Tanaka S, Masliah E, Ueda K. Association of monoamine oxidase A gene polymorphism with Alzheimer's disease and Lewy body variant. Neurosci Lett 2002;327:79-82.
40. Nishimura AL, Guindalini C, Oliveira JR, et al. Monoamine oxidase a polymorphism in Brazilian patients: risk factor for late-onset Alzheimer's disease? J Mol Neurosci 2005;27:213-7.
41. Zhou JN, Liu RY, Kamphorst W, Hofman MA, Swaab DF. Early neuropathological Alzheimer's changes in aged individuals are accompanied by decreased cerebrospinal fluid melatonin levels. J Pineal Res 2003;35:125-30.
42. Stahl SM, Markowitz JS, Papadopoulos G, Sadik K. Examination of nighttime sleep-related problems during double-blind, placebo-controlled trials of galantamine in patients with Alzheimer's disease Curr Med Res Opin 2004;20:517-24.
43. Inglis F, The tolerability and safety of cholinesterase inhibitors in the treatment of dementia. Int J Clin Pract Suppl 2002:127;45-63.